ADORA2A and Parkinson disease: Given that A2AR in different localizations have a different interactome [95] and different pharmacological profiles [96], it becomes important to consider that different optimal doses of different A2AR antagonists may be required to target the different A2AR responsible for synaptoprotection, neuroprotection, and motor benefits [30], a concern critical for the adequate and effective exploitation of A2AR antagonists in PD.